Related Experiment Video
Updated: Jul 16, 2026

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
Published on: May 10, 2016
Identifying carcinogenic hazards among pharmaceutical agents: An update from the IARC Monographs programme
Elisa Pasqual1, Andrew Kunzmann1, Julia Rezende da Silva1
1International Agency for Research on Cancer, World Health Organization, Lyon, France.
This review examines pharmaceuticals classified as human carcinogens by the International Agency for Research on Cancer (IARC). Pharmacoepidemiology data is crucial for identifying drug-induced cancer hazards and informing safety policies.
Area of Science:
- Oncology
- Pharmacoepidemiology
- Toxicology
Background:
- Review of pharmaceuticals evaluated for carcinogenicity by the International Agency for Research on Cancer (IARC) Monographs programme (1971-2024).
- Analysis of recommended evaluation priorities (2024-2029) for pharmaceuticals.
- Stimulating epidemiological research for human cancer and mechanistic evidence in hazard identification.
Purpose of the Study:
- To review the evaluation of pharmaceuticals classified as human carcinogens by IARC.
- To summarize recommended evaluation priorities for pharmaceuticals.
- To encourage research contributing to cancer hazard identification.
Main Methods:
- Extracted data on cancer in humans/animals and mechanistic evidence for IARC Groups 1, 2A, and 2B pharmaceuticals (1971-2026) from published IARC monographs.
- Summarized pharmaceuticals prioritized for evaluation (2025-2029) by the IARC Monographs Advisory Group.
- Highlighted available human cancer and mechanistic study data for prioritized pharmaceuticals.
Main Results:
- 77 pharmaceuticals evaluated: 24 Group 1, 13 Group 2A, 40 Group 2B.
- 22 pharmaceuticals prioritized for evaluation, including antineoplastic, hormonal, and immunosuppressant agents.
- High-priority drugs include cancer treatments (anthracyclines, cisplatin), GLP-1 agonists, paracetamol, and contraceptives, with evidence of increased malignancies.
Conclusions:
- Pharmacoepidemiology data, particularly cancer and mechanistic endpoints, significantly aids pharmaceutical cancer hazard identification within the IARC Monographs programme.
- These findings can inform policy for patient and occupational safety.
- Evidence from human studies and mechanistic data are key drivers for prioritizing pharmaceutical evaluations.
Related Concept Videos
Mutagenicity and Carcinogenicity
Physical Properties of Amines
Cancer Prevention
Some...
Bioactivation and Tissue Toxicity
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Pharmaceutical Poisoning: Potential Scenarios

![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)